FIELD: medicine. SUBSTANCE: method involves selecting pure cultures of pathogens. Their identification is carried out. Two or more species being detected, antilysozyme activity and ability for inactivating bactericide blood serum activity as ALA and AIBBSA, are to be determined, respectively. The properties being marked in at least one case of pathogens as ALA ≥ 5 mcg/ml for enterobacteria, ALA ≥ 3 mcg/ml for staphylococcus, ALA ≥ 1 mcg/ml for streptococcus and pseudomonades and AIBBSA 60% for every pathogen, long-term development of pyoinflammatory disease without pyoseptic complications is to be predicted. At least one of pathogens showing AIBBSA ≥ 60%, long-term development of pyoinflammatory disease with pyoseptic complications requiring repeated operative intervention is to be predicted. Enterobacterium antilysozyme activity being less than 5 mcg/ml, staphylococcus one being less than 3 mcg/ml, streptococcus and pseudomonades one being less than 1 mcg/ml, and at least one of pathogens showing AIBBSA ≥ 60%, short-term development of pyoinflammatory disease with pyoseptic complications requiring repeated operative intervention is to be predicted. EFFECT: early stage detection of patients with unfavorable prognosis; appropriate therapy course selection. 6 tbl
